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Key points 
• Novel kidney biomarkers can expose subtle and subclinical kidney disease that may 
otherwise remain undiscovered with conventional diagnostic assessment. 
• Active kidney injury biomarkers have the potential to establish a new understanding 
of traditional views of chronic kidney disease (CKD), including its early identification 
and possible mediators of its progression. 
• Sensitive and specific biomarkers are likely to lead to insights into clinical kidney 
disease and facilitate new diagnostic and therapeutic approaches. 
• Therapeutic approaches may be monitored to biomarker endpoints and logically 
adjusted or extended until the biomarker activity is nullified. 
 
The 2015 IRIS Napa Meeting 
In May, 2015 the International Renal Interest Society (IRIS), a veterinary society 
established to advance the scientific understanding of kidney disease in small animals, 
sanctioned the 2015 IRIS Napa Meeting. The meeting was conceived as a highly focused 
strategic planning forum composed of many of the profession’s recognized leaders in 
nephrologya to direct recognition and innovative solutions to evolving critical issues in 
veterinary nephrology.  The theme of the meeting was, “Re-evaluation and 
Understanding of IRIS Stage1 and Grade I Kidney Disease as Predictors of Progressive 
Kidney Disease.”  Since the inception of the IRIS CKD Staging and AKI Grading 
5 
 
systems to categorize and stratify kidney disease in animals1,2, there has been confusion 
and misunderstanding of the value and clinical utility of these early (non azotemic) 
categories.  The clinical relevance of these categories has been questioned, as has the 
justification to embed asymptomatic and non azotemic patients in the overarching 
understanding of kidney disease.  A significant focus of the Napa Meeting reflected on 
the relevance of early kidney disease and the importance of its recognition to the 
subsequent fate and outcomes of kidney disease discovered by conventional practices 
and methodologies.  
  The recognition of early, asymptomatic kidney disease is generally established 
on the basis of directed screening of at risk animals or as an incidental observation from 
routine testing of animals for other purposes.  What criteria define which animals to 
screen?  What evaluations are most accurate and sensitive on a screening panel?  Is 
there value to establish evidence-based risk assessment algorithms that generate a risk 
score providing cost-effective predictions to guide practice patterns for screening CKD 
Stage 1 and/or AKI Grade I?   Answers to these questions will help to establish the 
diagnostic and clinical significance to Stage 1 and Grade I kidney disease.   
Currently, kidney disease is documented and stratified by use of function 
markers that may reflect slow states of transition or relatively steady-state conditions.   
Conventional practice pattern rely on urine specific gravity, proteinuria, serum 
creatinine, and symmetrical dimethylated arginine (SDMA) to reflect chronic kidney 
disease (CKD) that may be static (non-progressive) or may be active and variably 
progressive.  We have relied on serum creatinine for at least a century to predict the 
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adequacy or inadequacy of kidney function with relative utility.3  More recently SDMA 
has become available to complement some of the short-comings of creatinine, but 
additional time is required to duly establish its role and acceptance.  (See Relford et. al. 
and Yeramilli et. al. in this edition)  Despite familiarity with creatinine for the diagnosis 
of kidney disease, its utility has been constrained by the misperception it is blinded to 
early and subclinical kidney dysfunction and its excessively broad reference range for 
dogs and cats.3  IRIS CKD Stage 1 encompasses the normal reference range for 
creatinine which creates confusion identifying this stage as CKD.  Documented CKD 
often is associated with the bias that the disease is advanced at the time of diagnosis, 
and the kidney fate is predetermined.  However, a patient recognized in a more 
advanced stages of kidney disease, by logical extension, must have started from or 
passed through a lesser category of kidney disease prior to its recognition.  Kidney 
disease that progresses from IRIS CKD Stage 1 to higher stages likely has undergone an 
episodic or ongoing active process promoting the progressive erosion of steady-state 
function.   
A functional diagnostic marker may fail to detect the underlying active 
component if offset by renal reserve, or if it is matched by compensatory adaptation of 
the residual kidney mass.  Only when active injury outpaces repair or compensatory 
adaptation will the progression become evident.4   Equally important, many animals 
with recognized CKD maintain relatively “static” or non-progressive kidney function 
over extended periods of time.40, 41  These patients may justify different diagnostic, 
monitoring, and therapeutic attention.  An important outcome of the Napa Meeting was 
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establishment of a strategic hypothesis for the recognition and understanding of early 
(IRIS CKD Stage 1) kidney disease.  Specifically, this hypothesis underscored the 
likelihood for underlying active kidney injury contributing to the risk for progression of 
CKD; or lack of an active component leading to stable kidney function.   
The Napa Meeting explored potential relationships between CKD and acute 
kidney injury (AKI).  Both IRIS CKD Stages 1 and IRIS AKI Grade I represent early 
kidney disease states which may not be recognized until they proceed to a more 
advanced classifications.  If progressive CKD is associated with active episodic or 
ongoing injury to the kidney, and if AKI is linked to progressive CKD (see below), 
could both these disease syndromes be explained by the same pathological process or 
processes progressing concurrently at different rates to establish both categories?  
Should early CKD and AKI be viewed as interconnected rather than separate clinical 
conditions?  To this issue, the following questions relative to early CKD and early AKI 
were proposed by the participants: 
1. Are IRIS CKD Stage 1 and IRIS AKI Grade I similar processes developing 
at different rates, or are they separate processes that should be viewed as 
interconnected?  “Is progressive CKD a slow-moving AKI”? 
2. Is IRIS CKD Stage 1 an active condition leading to progressive CKD or an 
inactive condition associated with stable kidney disease? 
3. Is IRIS AKI Grade I a marker that could proceed to a rapidly progressive 
AKI or a slowly progressive CKD? 
4. Are there better future definitions for IRIS CKD Stage 1? 
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The answers to these questions forecast the need to develop diagnostics to better 
distinguish active versues the absence of active kidney injury and progressive versus 
static CKD and to document the pattern and causes of progressive CKD.  If early kidney 
disease (IRIS CKD Stage 1) could be identified as active or inactive, there would be 
potential to alter the management and monitoring of the patient to minimize its 
progression to more advanced stages. 
 
Is there a need to distinguish two specific types of kidney disease: acute versus 
chronic? 
Historically, kidney disease has been broadly defined into two seemingly distinct 
categories, chronic kidney disease (CKD) and acute kidney injury (AKI).5, 6, 14 Each 
category of disease has distinctive features and has been defined by unique 
categorization schemes, the IRIS CKD Staging system for CKD and the IRIS AKI 
Grading system for AKI.1, 2   Chronic kidney disease is perceived as slow in onset, 
characteristically progressive over time, and irreversible; whereas AKI develops rapidly 
and maintains the potential for repair and return of kidney function.  Recently, these 
categories of kidney disease have been shown to interrelate, and their distinctions have 
become blurred at their interface.  Chronic kidney disease is a known risk factor for the 
development of AKI, and AKI is recognized increasingly as a potential mediator for 
progressive CKD and end-stage kidney disease.13, 14  
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Chronic kidney disease is defined by sustained functional and/or structural 
damage to the kidneys over a course greater than 2 to 3 months.1, 5 Decreasing kidney 
function recognized by reductions in glomerular filtration rate (GFR) or estimation of 
GFR by increasing serum creatinine or SDMA are the most common features 
identifying CKD in animals.5, 7 (See Relford, et. al. in this issue)  Chronic kidney disease 
is established initially by a singular or a combination of insults to the kidney that result 
in irreparable structural or functional damage to renal parenchyma that is repaired 
incompletely and promotes variable kidney dysfunction.  
Progression, or sustained worsening of kidney function over time, is a hallmark 
of CKD in most animals, but its pathogenesis remains elusive and likely is 
multifactorial. Equally elusive is the explanation why some animals with CKD maintain 
relatively stable kidney function and apparently fail to progress.  These differences in 
behavior may hold clues to explain the mechanisms of progressive CKD as well as 
therapeutic targets and intervention points to halt the process.  Multiple risk factors for 
developing CKD have been documented including age, hypertension, proteinuria, 
infectious agents, endocrine disease, breed predilections, AKI, and heart disease among 
others.  Progressive CKD is a natural consequence of an inability to resolve these risks 
or other co-morbidities in animals with established CKD.  Identification of progressive 
CKD in the absence of these identifiable co-morbidities or following resolution of initial 
insults has been more intangible.   
10 
 
To date, the timely recognition of animals with progressive CKD and those with 
static CKD has been constrained by the relative lack of early diagnostic predictors.  
Serum creatinine and SDMA are relatively static markers of kidney mass reflecting 
steady-state predictions of kidney function which may include renal reserve, 
compensatory adaptations to ongoing nephron loss in addition to discrete reductions of 
functional kidney mass.  Neither of these “static” (functional) kidney markers are 
sufficiently sensitive to signal early, subtle, and potentially ongoing kidney injury 
which may evolve slowly with a resultant decrease in functional renal mass. Other 
predictors of progression need discovery and validation.  Proteinuria has been 
associated consistently with risks for progression in both human and animal patients 
with CKD.  Urinary protein excretion has been shown to correlate with progressive 
CKD in cats and dogs, but urine protein:creatinine ratio has low specificity for CKD 
progression, and it is unclear if proteinuria is a marker for progression or participates in 
it development.8   Currently, there are few criteria in veterinary patients to project the 
risk for progression of CKD.  Prediction models in human patients are similarly 
problematic and subject to bias.9   
 Sustained and overt damage to the glomerulus or tubulointerstitium from 
primary diseases like hypertension, glomerulonephritis, or chronic pyelonephritis 
which are not fully resolved promote an expected progressive damage and an expected 
loss of functional kidney mass.   The risks, patterns, and mechanisms for progression 
from seemingly occult CKD remain unknown.    Progression of CKD to end-stage 
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kidney disease could occur step-wise from sporadic active insults which are either overt 
or subclinical and of similar or differing etiologies.  These episodic injuries could 
promote cumulative damage resulting in further dysfunction and concurrent reduction 
of GFR and GFR markers. (Figure 1)    Alternatively, metabolic or signaling disruptions 
to kidney structures intrinsically associated with the establishment of CKD or AKI 
could promote ongoing stresses or disordered metabolism within the residual renal 
mass which perpetuates sustained injury with a varying time course and further loss of 
kidney parenchyma and function.  The respective prevalence and influences of these 
alternative pathways is unknown.  Similarly, the underlying mechanisms participating 
in progression have been hypothesized widely but remain largely undefined.9, 10   
Regardless of which pattern or mechanism of CKD progression prevails in an 
individual patient, all appear to share a common feature of active stress or injury to the 
residual structures of the kidney.   
There is accumulating evidence from a variety of models of AKI proposing a 
sequence of effective adaptive or maladaptive events in cellular repair that likely 
influence the prevention or predisposition to progressive CKD.4, 11-18, 20   Following an 
acute insult, injured tubular epithelial cells may become fatally injured and undergo 
necrosis or apoptosis, proliferate and regenerate the damaged epithelium, or undergo 
failed regeneration but survive cell death in a state of cell cycle G2/M arrest.4, 13, 14, 15, 16, 
17, 27   Arrested cells reprieved from apoptosis, however, fail to participate in 
regenerative repair and upregulate maladaptive signaling pathways for myofibroblast 
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proliferation and fibrosis in the interstitium predisposing to progression of CKD.  
Tubular epithelia subjected to more severe or repeated injury, sustained or ongoing 
injury, or epithelia that are more senescent also are more susceptible to cell cycle 
arrest.13, 15, 16, 18   
These observations provide a speculative foundation for progression of CKD that 
may involve recurrent or sustained injury to the kidneys which promotes active 
interstitial inflammation and fibrosis.  These events remain clinically occult and 
undetected until there is a quantum decrement in functional renal mass ultimately 
detectable by traditional functional clinical markers.  Triggers for sustained or active 
injury could include unresolved primary disease (e.g., glomerulonephritis), co-morbid 
conditions (e.g., systemic hypertension, heart disease, and regional ischemia), chronic 
medications (e.g., ACEI, diuretics, antibiotics, NSAIDs), chronic inflammation, chronic 
immune stimulation, recurrent infection, and proteinuria among others.  
Independent of the nature of the insult to the kidney, a common theme for CKD 
progression appears to be active and ongoing stress, metabolic dysregulation, and loss 
of morphologic and functional integrity of the tubular epithelium leading to interstitial 
inflammation and fibrosis.  The tubular epithelial focus prevails whether the insult is 
pre-glomerular hemodynamic changes predisposing to subtle hypoxia; sustained 
glomerular disease promoting vascular rarefaction, proteinuria and reduced 
ultrafiltrate; tubular stress or inflammation; or post renal events associated with outflow 
obstruction.10, 13, 16, 19     
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A prevailing stress to tubular epithelia is persistent and severe exposure to 
protein escaping glomerular permselectivity.  An excessive protein load can dysregulate 
the normal cubilin and megalin receptor-mediated endocytosis of protein by proximal 
tubular cells and predispose these cells to atrophy and apoptosis.19   In addition, 
excessive reabsorption of protein and protein-bound substances including fatty acids 
may promote cellular stress responses that activate a variety of genes promoting 
proinflammatory cytokines, autophagy, and activated immune responses.  
Consequently, there is compelling evidence that proteinuria per se propagates a 
maladaptive cycle of tubular injury, epithelial degeneration, and scaring in the adjacent 
interstitium.19   
Recent experimental studies using both ischemia-reperfusion and toxic models of 
acute kidney injury, have provided an enhanced understanding how active, potentially 
sustained, and ongoing stresses to tubular epithelia can promote progressive cellular 
maladaptation and inflammatory and fibrotic consequences in the tubulointerstitium.  
Of further note, these active cellular events are temporally disassociated from 
worsening GFR or markers of kidney function.17, 21    Despite its high metabolic activity 
and oxygen requirements, the inner cortex and outer medullary segments of the kidney 
exist in a state of tenuous oxygenation which is highly regulated in health but subject to 
profound inadequacy with vascular compromise, hypoperfusion, and relative hypoxia.  
With either subtle or profound tubulointerstitial injury, this tenuous vasculature can be 
secondarily compromised further disrupting oxygen delivery and the balance between 
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tubular energy demands and oxygen availability.  Kidney injury can be directed 
specifically to the vasculature promoting endothelial cell activation, leukocyte and 
platelet aggregation, and compromised perfusion and oxygen delivery to the tubular 
epithelium.  More importantly, tubular epithelial injury subsequent to oxidative stress 
activates vasoconstrictive signals promoting a vicious cycle of heightened ischemia, 
progressive vascular rarefaction, and stimulation of growth factors which signal 
interstitial fibrosis and progressive hypoxia.10, 13, 15, 16, 17, 18 
Cellular stress of various causes also stimulates a diverse spectrum of directed 
pathways leading to dysregulated apoptosis, local inflammatory responses, and/or 
interstitial fibrosis which have been associated with progressive CKD. 10, 13, 15, 16, 17, 18  
One of these maladaptive cellular responses is associated with accumulation of 
inappropriately processed or unfolded proteins in the endoplasmic reticulum (ER).17, 22    
Cellular adaptations to ER dysregulation are initiated to adjust the translation, 
translocation, folding, and degradation of ER proteins as protective mechanisms, but 
they simultaneously promote cellular autophagy.17, 22  Autophagy is a cellular 
“cleanup” process in which damaged cytosolic constituents and organelles are 
encapsulated in autophagosomes and degraded for reutilization in cytosolic lysosomes.  
Autophagy is a protective adaptation to protect the cell from death.  However, in 
experimental models of kidney diseases, the misfolded protein-induced dysfunction of 
the ER and mitochondria can stimulate pro-inflammatory responses via nuclear factor-
κB (NF-κB) upregulation and mediation of transcription of target genes for 
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inflammatory interleukins, tumor necrosis factor-α, and adhesion molecules. 17, 22 
Sustained or severe cellular stresses over stimulate these adaptive responses and 
activate downstream signaling pathways for apoptosis of the disrupted cell. 
These observations illustrate that diverse and seemingly uncoordinated events or 
reactions often are channeled through common metabolic junctions to promote a 
common or universal cellular response.  Similarly, the kidney responds to many overt 
stresses and injuries with a series of adaptive reactions fundamentally intended to 
reestablish cellular integrity and promote cell survival.  However, when the stress or 
injury is sustained or insurmountable, these same cellular responses may become 
maladaptive or the cell is programmed to die.4, 15   These latter responses are expressed 
clinically as acute kidney injury with variable recovery, kidney death, or more subtly as 
progressive chronic kidney disease.   If the kidney recovers, many of these adaptive 
cellular responses become pathways for the transition of overt acute kidney injury to 
progressive chronic kidney disease.  The majority of models highlighting this 
progression have focused on the continuum from AKI to CKD. 4, 11-18, 20, 21, 27  As an 
overview, in many circumstances, the apparent resolution of AKI, which by all clinical 
indications is resolved, leaves behind pathophysiologic embers that smolder 
asymptomatically to sustain tubular and vascular injury which slowly and 
progressively erode functional renal mass.  The erosion is perpetuated by pro-
inflammatory messengers that at first are deemed adaptive but ultimately may become 
maladaptive.   
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Identification of Progressive CKD: The Search for Active Injury Markers 
In distinction to the AKI to CKD scenario (outlined above), progressive CKD is 
recognized in the majority of animals in the absence of an overt AKI.  The progression is 
variable over time and recognized primarily by worsening changes in markers of 
steady-state kidney function like serum creatinine or SDMA resulting in increased CKD 
Stage over time.  An animal with a serum creatinine of 1.8 mg/dL previously classified 
as IRIS CKD Stage 2 who subsequently is recognized with a serum creatinine of 3.5 
mg/dL and classified as IRIS CKD Stage 3 must have experienced interim kidney injury 
resulting in the progression. Where there is less attention to trending kidney function 
markers or staging of CKD, the progressive nature of CKD may be signaled by the 
appearance and worsening of overt clinical features of kidney dysfunction including 
inappetence, weight loss, polydipsia, polyuria, micturition disorders, lethargy, and 
vomiting.  In further distinction to the AKI to CKD scenario, many animals are 
identified with CKD of unknown etiology and no precedent acute injury in which 
kidney function and health appears stable for extended periods of time.    To date it is 
unknown why some animals manifest progression and some do not, and in the absence 
of overt and persistent kidney disease (e.g., pyelonephritis, glomerulonephritis, 
nephrolithiasis, hypertension, nephrotoxic drugs), there are no diagnostic features of 
CKD that forecast which individual animals are predisposed to progression and which 
are not.   
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Also unknown is the pattern or nature of the injury promoting progression.  For 
some animals, progression may be provoked by sequential episodic bouts of kidney 
damage that remain subclinical and undetected. (Figure 1) These episodes may escape 
functional detection and remain unrecognized clinically until the episodic damage 
exceeds the renal reserve capacity or compensatory adaptations of the kidneys.4, 23   At 
this stage there will be evident worsening of steady-state function markers and 
progressive increases in CKD Stage.  Alternatively or in combination with episodic 
damage, underlying mechanisms promoted by the existing CKD or an ongoing but low-
grade AKI may perpetuate cellular stresses or insults that direct sustained injury to the 
kidney.  Again, this ongoing damage may remain undetectable until parenchymal loss 
exceeds functional compensations.  Either of these potential patterns of progression 
may be too subtle to be recognized by clinical features or evidence of ill health.  
Similarly, our current definitions of AKI Grade and CKD Stage may be too insensitive 
to reveal ongoing or episodic active kidney injury until there has been a finite change in 
static kidney function predicted with currently available test.  Unfortunately, static 
kidney function tests only detect the impact of these active processes after substantial 
functional or structural damage has occurred.4, 24  
A sensitive and specific predictor that discriminates whether a patient is likely to 
progress or remain stable with CKD would provide tremendous diagnostic and 
therapeutic advantage.4, 17, 23  For patients with identified progressive CKD, this could 
provide earlier opportunity to seek subclinical conditions which might be injuring the 
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kidneys and institute more timely monitoring of the disease.  It also would provide an 
opportunity to initiate therapies that might ameliorate progression or development of 
clinical signs as well as indicate the effectiveness of therapeutic interventions.  If a 
therapeutic regimen failed to convert the patient to a non-progressive status, there 
might be justification to modify the therapy before additional loss of kidney function 
occurred.   
There has been growing interest and research in human nephrology directed at 
discovering biomarkers that would predict the early onset of AKI.4, 24, 25, 26   Similar efforts 
are underway in veterinary medicine and show great promise.28-36 (See also, Yerramilli in 
this issue) An AKI biomarker should be detectable in urine and/or plasma such that it can 
be assessed routinely and serve as an indicator of kidney function or dysfunction or 
response to injury.  The ideal marker should reflect kidney specific events, be unique and 
specific to the kidney, and reflect very early and potentially sustained phases of the 
pathogenesis and repair processes.  Additionally, the ideal marker should reflect the extent 
of these ongoing processes, their location, changes in these processes in response to 
therapeutic intervention over time, and potentially the etiological insult.  A singular 
biomarker is highly unlikely to be able to distinguish both processes associated with 
induction of the AKI and also events associated with repair of the injury.  However, the 
absence of a biomarker associated with active injury may predict resolution of the active 
phase.  More realistically, a panel of biomarkers predictive of differing phases of induction, 
maintenance, and repair of AKI might serve these ideal goals.      
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Candidate Biomarkers for Active Kidney Injury 
Novel AKI biomarkers have been screened and selected for their prediction of early 
and sensitive alterations of normal cellular processes in the kidney and historically have 
been exploited for their potential to detect early acute kidney injury. 4, 24, 25, 26    However, 
this restricted focus to AKI constrains their broader and potentially important application 
to CKD.  Kidney-specific biomarkers that localize to functional renal tubular epithelia (or 
other kidney-specific loci) and respond to diverse stresses or disruption of normal cellular 
function have potential to signal the early, specific, and sensitive existence of kidney injury 
and are perhaps better termed “active kidney injury” biomarkers.  An “active kidney 
injury” biomarker could expose ongoing or progressive kidney injury in advance of 
conventional diagnostic methods that document consequent alterations in glomerular 
filtration rate or substantive loss of functional parenchyma over time.   
With this perspective, static CKD may be redefined as a stable, unchanging state of 
long-standing and irreversible loss of varying degrees of kidney parenchyma and function 
associated with the absence of detectable active kidney injury.  It would be characterized 
by stable biochemical markers of kidney function (e.g., serum creatinine and/or SDMA 
concentration) over a prolonged but variable period of time of perhaps greater than 5 to 6 
months.  Progressive CKD, on the other hand, is a state of long-standing and irreversible 
loss of variable degrees of kidney parenchyma and function likely associated with 
persistent or intermittent active kidney injury over an arbitrary interval of 2 to 4 month 
interval.  The implied “active injury”, albeit subtle or occult, secondarily generates 
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cumulative damage to the kidney and an ongoing loss of structural kidney parenchyma 
and function.  These ongoing pathologic processes ultimately are detected by conventional 
biochemical markers of kidney function and increases in CKD Stage.  Evidence of serum 
creatinine and/or SDMA trending upward is the current standard for identifying 
progressive CKD, but these changes can be relatively slow to develop and detect injury 
after it has already reduced kidney function. (Figure 2) Detection of biomarkers associated 
with “active kidney injury” in animals with CKD has the potential to predict or identify 
those patients whose underlying kidney disease is ongoing and likely to progress in 
advance of biochemical markers whose short-term values reflect relatively static kidney 
function.  
Many candidate serum and urinary biomarkers have been assessed in human 
medicine7, 18, 23, 24, 26, 27,, and many of the promising markers are now being evaluated and 
validated in animals. 28, 36 (See also, Yerramilli in this issue)   Some of the most promising 
candidates include urinary proteins that reflect functions or cellular processes specific to 
the kidney that are disrupted by pathophysiologic events secondary to injury or cellular 
stress.  Retinol binding protein (RBP), cystatin C, cystatin B, kidney injury molecule-1 
(KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, liver-type fatty 
acid-binding protein L-FABP), tissue inhibitor metalloproteinase-2 (TIMP-2), and IGF-
binding protein 7 are among the most actively pursued. 7, 18, 23, 24, 26, 28, 36 (See also, Yerramilli 
in this issue)  
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Retinal binding protein is a 21 kDa protein produced in the liver and serves as the 
principal carrier of vitamin A in the circulation.  When not complexed to larger plasma 
proteins, free RBP is freely filtered by the glomerulus and subsequently reabsorbed by 
megalin-mediated endocytosis and catabolized by the proximal tubular epithelium.  With 
proximal tubular dysfunction RBP can escape reabsorption and appear abnormally in 
urine.28, 37  This linkage to tubular dysfunction has established RBP as a candidate for early 
identification of kidney injury.  Retinal binding protein has been evaluated in dogs 
associated with a variety AKI models, and its appearance precedes routine clinical 
predictors as an early marker of AKI.  However, urinary RBP is only loosely associated 
with proximal tubular dysfunction and is nonspecific for active injury to the tubular 
epithelium.28, 37    
Cystatin C is a 13 kDA cysteine protease inhibitor constitutively produced by most 
cells and subsequently circulated in blood after release from the cells.  It is freely filtered 
across the glomerulus and subject to proximal tubular reabsorption from the filtrate and 
degradation in the proximal epithelia.  Like RBP, dysfunction of megalin-mediated 
endocytosis from acute injury or decreased reabsorptive capacity results in urinary 
detection of cystatin C, and its increased renal excretion.28  Cystatin C has been proposed as 
an early predictor of kidney dysfunction.  However, it also lacks specificity for active 
kidney injury, is not uniquely produced by kidney cells, and, as for any freely filtered 
protein, is confounded by excessive proteinuria which might promote its urinary excretion 
without substantive active or ongoing tubular injury.  
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Despite the interest and efforts to validate KIM-1 as an AKI biomarker in human 
patients, 7, 18, 23, 24, 26, 27 in preliminary investigations, there has been no success (working 
with the developers) to detect KIM-1 in dogs with any of the available human, primate, or 
rodent assays for KIM-1. (Personal communication, Drs. Carrie Palm and Larry D. Cowgill) 
 Neutrophil gelatinase-associated lipocalin (NGAL) is a 24-kDa protein initially 
identified bound to gelatinase in specific granules of neutrophils. Subsequently, NGAL 
expression has been demonstrated by a variety of epithelia and specifically is up-regulated 
more than tenfold in renal tubular epithelia within the first few hours following ischemic, 
obstructive, and toxic kidney injuries in human patients with AKI, naturally acquired 
kidney disease in dogs, and experimental models of AKI in dogs.24, 25, 27, 28-36, 38   Recent 
studies in dogs with experimental gentamicin-induced AKI and in dogs with naturally 
acquired AKI, demonstrated NGAL sensitivities and specificities approaching 95% or 
greater for the early detection of AKI.30, 31   A commercially available assay for detection of 
canine NGAL is availableb and has been validated for early detection of AKI.  While 
urinary NGAL currently is promising, it lacks uniqueness with regard to its cellular origins 
and specificity for kidney injury, and it can be influenced by co-morbid diseases.    
Other promising biomarkers include serum inosine, urinary clusterin, and urinary 
cystatin B which are under active evaluation in a variety of dog and cat models of AKI, 
naturally acquired active kidney injury, and progressive CKD. (See Yerramilli in this issue) 
The attraction of these novel biomarkers is their exclusive origins to renal tubular epithelia, 
integral association with cellular activities coupled to stress or damage, and their highly 
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specific analytical evaluation.  As such, these markers offer the potential sensitivity and 
specificity to forecast active and sustained disruption of normal cellular processes as 
harbingers of subsequent loss of steady-state kidney functions or residual renal mass. 
Although the clinical directive for these kidney-specific biomarkers is to facilitate the 
diagnosis of early AKI, preliminary studies have documented their sensitivity for kidney 
disease beyond AKI.  Their potential extends to document subclinical yet active and 
ongoing kidney injury associated with concurrent urinary diseases or other systemic illness 
that may impact the kidney secondarily.  For future diagnostics, individual markers or a 
panel of novel markers could provide the potential to recognize subtle and often subclinical 
kidney disease that would otherwise remain undiscovered until more substantial injury 
and dysfunction triggers alterations in conventional diagnostics.  Even more importantly, 
“active kidney injury” biomarkers have potential to establish a new understanding of our 
traditional views of CKD including early identification and possible mediators of its 
progression.  Novel, kidney-specific biomarkers will likely establish a completely new and 
sophisticated paradigm in our approach to the understanding, diagnostic evaluation, and 
treatment of kidney disease in dogs and cats.  However attractive initially, the value and 
clinical utility of any novel kidney biomarker to forecast outcomes or direct treatment must 
be founded on the basis of well-designed and prospective controlled longitudinal studies 
of patients with CKD. 
Potential Application of Novel Active Injury Kidney Biomarkers to Forecast Early 
Kidney Injury 
24 
 
Early recognition of AKI:  Urinary NGAL has been shown to be a sensitive and early 
predictor of AKI in dogs with both experimentally-induced and naturally occurring AKI 
and may precede detection of kidney disease by serum creatinine or SDMA by more than a 
week.29, 30, 31, 34 (Figure 3)  In dogs with naturally acquired urinary tract disease, urinary 
NGAL was a highly sensitive and specific predictor of AKI including dogs categorized as 
IRIS AKI Grade I.30   
In collaboration with IDEXX Laboratories, the one of the authorsc similarly has 
evaluated the diagnostic performance of serum inosine, urinary clusterin, and urinary 
cystatin B in a gentamicin-induced model of AKI in dogs.  (See Yeramilli in this issue) In 
this model, each of these novel biomarkers demonstrated a robust response or change 
within 72 to 120 hours from the induction of gentamicin documenting early and ongoing 
active injury.  Each marker forecast the active kidney injury 7 to 10 days before any 
identifiable change in serum creatinine or SDMA. (See Yeramilli in this issue)  These 
preliminary observations have provided optimism they may serve as unique diagnostic 
tools to disclose kidney injury at a time when it is otherwise diagnostically camouflaged.   
Active kidney injury in urinary tract infection:  In a previous study evaluating the 
specificity of urinary NGAL as a predictor of AKI in dogs, a significant increase in its 
urinary expression was observed in dogs with lower urinary tract disease (infection, 
neoplasia, urolithiasis) compared to healthy dogs.30  As NGAL was identified originally 
as a component of neutrophil granules and is upregulated in response to inflammatory 
signals, it was tenable neutrophil associated inflammation could have been the source 
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of urinary NGAL in these dogs.39  However, it is difficult to exclude the presence of 
subclinical kidney involvement in this lower urinary tract cohort.  The increased 
urinary NGAL expression may have forecasted kidney involvement that was otherwise 
subclinical and undetectable.   
 
To gain preliminary insight into this question, in collaboration with Drs. Shelly 
Vaden and Murthy Yerramilli, the one of the authorsc recently has screened urine from 
36 dogs with documented urinary tract infection for the presence of urinary cystatin C, 
urinary NGAL, and urinary clusterin as predictors of concurrent active kidney injury.  
No dog had clinical evidence of AKI although 6 dogs (17%) had historical CKD.  The 
urine was considered positive for active kidney injury if at least 2 of 3 biomarkers were 
above the normal threshold or if urinary clusterin (of renal tubular origin) alone was 
above the reference threshold.  For the 30 dogs with no documented CKD, 43% 
demonstrated biomarker predicted active kidney injury, 37% had no biomarker 
predicted active kidney injury, and 20% demonstrated equivocal biomarker activity. 
(Table 1, excludes the equivocal group)  Although these data are preliminary and 
require additional prospective evaluation and validation of the long-term outcomes of 
these cases, they might suggest a large proportion of dogs with active urinary tract 
infection may simultaneously have upper tract kidney involvement promoting 
subclinical and otherwise undetectable active injury.  Identification of active kidney 
injury concurrent with lower urinary tract disease may suggest the kidneys are 
concurrently infected and potentially a source for recurrent infection of the lower 
26 
 
urinary tract. If not infected, the active injury may involve alternative mechanisms 
associated with lower tract infection and pose a risk for erosion of renal reserve and 
progressive CKD.  If these findings are confirmed by further validation studies, it 
suggests a new paradigm and significance to urinary tract infection and portends new 
diagnostic and therapeutic responsibilities.   
 
Active kidney injury in acute and chronic cardiorenal syndrome: Acute and chronic 
cardiorenal disorders are another clinical arena in which the kidney may be subjected to 
subclinical and potentially sustained active injury secondarily to disease, failure, or 
management of primary cardiovascular disease.  Severe and persistent heart failure is 
commonly associated with progressive CKD that may be punctuated by episodes of 
acute kidney decompensation concurrent with decompensation of cardiac function or 
escalation of drug therapy. (Figures 2)  Active kidney injury biomarkers may facilitate 
recognition of the incipient kidney damage.  This would permit more conscientious 
management of the cardiac disease and proactive preservation of kidney function and 
protection from kidney injury with its management.  (Figure 4) 
  
 Figure 2 illustrates the influence of progressive venous congestion on the kidneys 
(congestive nephropathy) subsequent to right heart failure and the development of 
ascites and increased intraabdominal pressure.  With abdominocentesis the 
intraabdominal pressure and congestion are relieved temporarily with an associated 
dramatic improvement of the active injury markers (urine clusterin and serum inosine) 
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with the initial abdominocentesis.  Although improved, the markers further illustrate 
the ongoing kidney injury associated with ongoing cardiac disease and progressive 
congestion between abdominocentesis procedures and their prediction of the 
progressive CKD.   
 
Is Progressive CKD a Slow Moving AKI:  A New Look at CKD 
 
 As discussed and illustrated above, novel kidney biomarkers can expose subtle 
and subclinical kidney disease that may otherwise remain undiscovered with 
conventional diagnostic assessment.  More importantly, “active kidney injury” 
biomarkers have potential to establish a new understanding of our traditional views of 
CKD including its early identification and possible mediators of its progression.  In a 
recent evaluation of urinary NGAL in dogs with kidney disease, there was significantly 
greater NGAL excretion in dogs with CKD than noted for healthy control dogs or those 
with lower urinary tract disease.30   The urinary NGAL excretion was clearly less than in 
dogs with AKI, but this observation suggested some degree of active injury may be 
ongoing in these dogs absent the typical presentation of acute-on-chronic disease.  
Similar findings were reported for serum NGAL in dogs with CKD, in which serum 
NGAL was significantly higher than control dogs and increased with IRIS CKD Stage.  
However, changes in serum NGAL are less specific than urine NGAL for predicting 
active kidney injury.32   
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 Progressive CKD generally develops in dogs with heart disease as the heart 
disease transitions from compensated to incipient or overt failure or with escalation in 
cardiac therapy.  Concurrent with this transition in cardiac function, there is expression 
of active kidney injury markers (an IRIS AKI Grade I? or IRIS CKD Stage 1?) which 
precedes the temporal progression to more advanced CKD Stages. (Figure 2)  Absent 
active injury, kidney function typically remains stable.  (Figure 5)  Similarly, as 
suggested in Table 1, animals with urinary tract infection and identifiable “active 
kidney injury” biomarkers might be classified as IRIS AKI Grade I or CKD Stage 1 
(depending on the duration of infection and initial creatinine concentration) on the basis 
of biomarker expression  but by most other criteria would otherwise have unrecognized 
kidney disease.  With persistent expression of “active injury kidney” biomarkers, there 
would ultimately be the expectation for transition to higher grades or stages of kidney 
disease and the detection of progressive CKD over time.   
 
 With this overview, a hypothesis has been proposed that progressive CKD may 
result from clinically occult or overt acute insults to the kidneys which are episodic or 
sustained in character (a slow-moving or sustained AKI) subsequent to exposure to 
diverse processes including metabolic and/or physiologic stresses.  Documentation of 
active and especially persistently active kidney injury may be predictive of patients who 
are at risk for progression of CKD.  Patients where evidence of active kidney injury is 
absent are more likely to maintain stable kidney function.  To support this hypothesis, 
prospective studies involving canine and feline patients with well characterized CKD 
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are need. The advent of “active kidney injury” biomarkers is likely to provide a 
renewed perspective and clinical significance to both IRIS CKD Stage 1 and IRIS AKI 
Grade I classifications.  Although patients with these classifications are non azotemic 
and generally asymptomatic, detectible “active kidney injury” markers may provide 
justifiable criteria for them to be classified with early kidney disease thus distinguishing 
them from animals with normal kidneys.  IRIS CKD Stage 1 and IRIS AKI Grade I 
classifications identified on the basis of biomarker criteria warrant heightened clinical 
significance as a recognizable gateway to more advanced kidney disease and 
progressively worsening kidney function.  It is worth noting that the transition from 
Stage 1 to Stage 2 CKD is associated with proportionally greater loss of functional renal 
mass than occurs with the transition between more advanced CKD Stages.  When 
followed over time or, ideally, coupled with markers of kidney repair, Stage 1 or Grade 
I classification might be further defined as “continued active”, “resolving”, or “inactive” 
to guide clinical decision making and therapeutic monitoring.   
 
Sensitive and specific biomarkers are likely to lead to new insights into clinical 
kidney disease and facilitate new diagnostic and therapeutic approaches.  Detection of 
active kidney injury (whether classified as CKD or AKI) may require a new designation 
depending on whether the patient’s condition resolves, fails to develop progressive 
clinical manifestations over time, or  progresses to overt clinical disease.  Given the 
common pathophysiologic foundations and mediators working in the same cellular 
milieu, the distinctions between CKD and AKI might be viewed more interactively as a 
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singular process in both early manifestations and advancing stages.  It is easy to foresee 
new opportunities and applications for biomarker diagnostics and their applications for 
early recognition of kidney injury associated with: 
1. Critical care  
2. Systemic diseases and their management including (e.g., heart failure, 
proteinuria, infectious disease, immune-mediated disease) 
3. Anesthesia and invasive procedures. 
4. Animals presenting for vague illness 
5. Acute-on-chronic kidney disease and progression of CKD 
 
If validated for specificity, sensitivity, and clinical utility, to be useful 
diagnostically, clinicians will need to be proactive in testing patients at risk for active 
kidney injury before the disease is identified by conventional diagnostic parameters or 
overt clinical signs.  The established use of “active kidney injury” biomarkers will 
require changes in practice patterns related to CKD and its potential progression.  
Clinicians by necessity will need to recognize and anticipate the potential risks and 
clinical circumstances that might predispose to progressive CKD including comorbid 
diseases (e.g., hypertension, pre-existing kidney disease, heart failure, pancreatitis, heat 
stroke, vomiting), medications (e.g., ACEI, diuretics, antimicrobials, NSAIDs), and 
diagnostic and therapeutic procedures (e.g., anesthesia, surgery, dentistry, contrast 
administration).   
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 This potential new diagnostic paradigm also will require an updated consensus 
for diagnostic and therapeutic responses to Stage 1 or Grade I kidney injury.  It 
promises answers to the questions, what triggers or processes promote progression of 
CKD; and how can progression be recognized and potentially mitigated at its earliest 
stage to preserve kidney function.  Similarly, therapeutic approaches may be monitored 
to biomarker endpoints and logically adjusted or extended until the biomarker activity 
is nullified.   
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Nabity, Scott Brown.  IDEXX Sponsorship Team: Roberta Relford, Jane Robertson, 
Murthy Yerramilli, Jason Lee, Troy Goddu, Leif Lorentzen, Donald McCarann, Lori 
Jackowitz. 
bAbbott Laboratories, Abbott Park, IL 
cLarry D. Cowgill 
 
 
 
  
33 
 
Figure Legends: 
 
Figure 1.  Schematic illustration of progressive CKD causing a decrease or worsening in 
functional kidney mass (or GFR) over time in response to step-wise or episodic  insults 
to the kidney (upper panel) or subsequent to sustained active kidney injury resulting 
from intrinsic stress or disordered metabolism associated with the established CKD 
(lower panel).   
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Figure 2.  Progressive chronic kidney disease (CKD) in a dog with mitral and tricuspid 
valvular insufficiency and regurgitation and right-sided congestive heart failure, ascites, 
and increased intraabdominal pressure.  Both NTproBNP and cTroponin I (not shown) 
were markedly elevated consistent with heart failure.  (Upper Panel)  Changes in serum 
creatinine (solid squares) and IDEXX SDMA™ (open circles) over time illustrating 
progressive worsening of kidney function. The solid and dashed horizontal lines 
represent the upper reference range for creatinine and IDEXX SDMA™, respectively.  
(Lower Panel) Associative changes in the “active kidney injury” biomarkers, urine 
clusterin (open triangles) and serum inosine (closed circles), to periodic 
abdominocentesis (arrows) and decreased intraabdominal pressure.  The mixed dashed 
horizontal line represents the lower reference threshold for serum inosine and the 
dotted horizontal lines represents the upper reference range for urine clusterin.  Note 
the marked improvement in both urinary clusterin and serum inosine subsequent to 
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institution of medical therapy and abdominocentesis (arrows) on day 0.  Although 
improved, both markers demonstrate only transient resolution of the ongoing kidney 
injury which progresses over time and between abdominocentesis procedures as the 
congestive heart failure progresses.  The biomarker-predicted active injury is further 
associated with the progressive CKD. 
 
 
 
 
 
 
Figure 3.  Changes in urine NGAL (solid triangles and curve) and serum creatinine 
(solid circles and dashed curve) in an experimental model of gentamicin nephrotoxicity 
in a dog.  Gentamicin was injected subcutaneously twice daily for 16.5 days (shaded 
area) until the serum creatinine increased by 50%.  Urinary NGAL predicts the “active 
kidney injury” by day 5 (solid arrow) whereas the AKI was not recognized until day 14 
by IRIS AKI guidelines (open arrow).  Note the discontinued left axis as urinary NGAL 
increased by more than 480 times the baseline concentration to a peak value to 264,000 
pg/mL at day 19 before decreasing to the baseline over the subsequent 26 days.  (Data 
from Palm, et. al., 2016: reference 31) 
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Figure 4.  Changes in conventional function test and novel “active kidney injury” 
markers in a dog with progressive valvular heart disease and impending cardiac 
failure.   Cardiac therapy including Lasix and ACE inhibition was started on Day 0..  By 
Day 6, the dog’s cardiac signs had improved.  However, twelve hours following 
discharge on day 6, the dog was represented to the emergency service for acute 
respiratory signs and heart failure secondary to a ruptured chordae tendineae requiring 
a rapid escalated the cardiac medications (arrow).   (Upper Panel)  Changes in serum 
creatinine (solid squares) and IDEXX SDMA™ (open circles) over time. The solid and 
dotted horizontal lines represent the upper reference range for creatinine and IDEXX 
SDMA™, respectively.  (Lower Panel) Associative changes in the “active kidney injury” 
biomarkers, urine clusterin (open triangles) and serum inosine (closed circles) over 
time.  The solid line represents the lower reference threshold for serum inosine, and the 
dotted horizontal line represent the upper reference range for urine clusterin.  The 
initial decrease in serum inosine suggest active kidney injury in response to the 
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impending cardiac failure.   The initial medical management for incipient congestive 
heart failure resulted in a marked improvement (increase) in serum inosine as a 
measure of resolving active kidney injury/stress between day 0 and day 6.  The 
subsequent acute decompensated heart failure and escalation of the medical 
management (arrow) promoted biomarker-predicted active kidney injury (decreased 
serum inosine and increased urinary clusterin) which persisted at a low level with 
compensation of the heart failure.  The active kidney injury was not detected by serum 
creatinine or IDEXX SDMA™. 
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Figure 5.  Changes in conventional markers of kidney function and novel “active 
kidney injury” markers in a dog with compensated mitral valvular heart disease.  
(Upper Panel)  Changes in serum creatinine (solid squares) and IDEXX SDMA™ (open 
circles) over time. The solid and dotted horizontal lines represent the upper reference 
range for creatinine and IDEXX SDMA™, respectively.  (Lower Panel) Associative 
changes in the “active kidney injury” biomarkers, urine clusterin (open triangles) and 
urine NGAL (closed diamonds) over time.  The solid and dotted horizontal lines 
represent the upper reference ranges for urine NGAL and urine clusterin, respectively.  
Note with stable and compensated heart failure, there is remarkable stability of kidney 
function and no biomarker-predicted active kidney injury over an extended period of 
time.   
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Table 1.  Blood and urine analytes from 30 dogs with documented urinary tract 
infection and no evident kidney involvement. 
Test 
(units; reference range) 
No Biomarker Evident 
Kidney Injury 
(n = 11) 
Biomarker Predicted 
Kidney Injury 
(n = 13) 
Clinical Parameters 
Median (range) 
Creatinine (mg/dL; 0.5-1.5 ) 0.9  (0.4-1.2) 0.9  (0.4-1.2) 
BUN (mg/dL; 9-31) 14.0  (3-21) 21  (8-75) 
IDEXX SDMA™ (µg /dL <14) 8.0  (6-16) 12.0  (7-17) 
Uprot/creat (< 0.5) 0.26  (0.04-0.89) 1.46  (0.02-8.85) 
Urine Specific Gravity 1.017  (1.006-1.032) 1.025  (1.013-1.042) 
uWBC  (/hpf; 0-5)  10 (0->500) 0 (0-20) 
uRBC   (/hpf; 0-5) 15 (0->500) 0 (0-15) 
Urinary Biomarkers 
Median (range) 
uCystatin C  (ng/mL,<300) 57  (1-115.7) 370  (29->2500) 
uNGAL  (ng/mL,<10) 2.6  (1.6-5.8) 40.4  (0.26-220.1) 
uClusterin  (ng/mL,<600) 97  (0-274) 2010  (119-2527) 
 
BUN, blood urea nitrogen; IDEXX SDMA™, IDEXX Laboratories symmetrical dimethylated arginine; 
Uprot/creat, urine protein/creatinine ratio; uWBC, urine white blood cell count; uRBC, urine red blood 
cell count; uCystatin C, urine cystatin C; uNGAL, urine neutrophil gelatinase-associated lipocalin; 
uClusterin, urine clusterin. 
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